Analysis of xenograft tumor growth derived from BRCA1-mutated and BRCA1-wildtype TNBC cell lines showed that co-treatment with selinexor and olaparib had a synergistic effect on tumor inhibition as compared to selinexor or olaparib alone. The gene discussed is BRCA1; the disease is neoplasm.